A plea to reduce or replace fetal bovine serum in cell culture media

Anderson NL, Anderson NG (2002) The human plasma proteome. History, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867

Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A (2004) The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3:311–326

Asher DM (1999) Bovine sera used in the manufacture of biologicals: current concerns and policies of the US Food and Drug Administration regarding the transmissible spongiform encephalopathies. Dev Biol Stand 99:41–44

Bohn B (1995) Fatal bovine serum. Nat Biotechnol 13:926–927

Brunner D, Frank J, Appl H, Schöffl H, Pfaller W, Gstraunthaler G (2010) Serum-free cell culture: the serum-free media interactive online database. ALTEX 27:53–62

Dormont D (1999) Transmissible spongiform encephalopathy agents and animal sera. Dev Biol Stand 99:25–34

Even MS, Sandusky CB, Barnard ND (2006) Serum-free hybridoma culture: ethical, scientific and safety considerations. Trends Biotechnol 24:105–108

FDA (2013) US Food and Drug Administration; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?ID=117863

Fujimoto B (2002) Fetal bovine serum—supply vs. demand? Art Sci 21:1–4

Gstraunthaler G (2003) Alternatives to the use of fetal bovine serum: serum-free cell culture. ALTEX 20:275–281

Gstraunthaler G, Lindl T (2013) Zell- und Gewebekultur, 7th edn. Spektrum Springer Verlag, Heidelberg

Hodgson J (1991) Checking the sources: the serum supply secret. Nat Biotechnol 9:1320–1324

Hodgson J (1993) Fetal bovine serum revisited. Nat Biotechnol 11:49–53

Hodgson J (1995) To treat or not to treat: that is the question for serum. Nat Biotechnol 13:333–343

Jochems CE, van der Valk JBF, Stafleu FR, Baumans V (2002) The use of fetal bovine serum: ethical and scientific problem? ATLA 30:219–227

Nielsen O (1995) Changing serum’s mind-set. Nat Biotechnol 13:626

Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS (2011) The human serum metabolome. PLoS ONE 6:e16957

Rauch C, Feifel E, Amann E-M, Spötl HP, Schennach H, Pfaller W, Gstraunthaler G (2011) Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. ALTEX 28:305–316

Shailer C, Corrin K (1999) Serum supply: policies and controls operating in New Zealand. Dev Biol Stand 99:71–77

van der Valk J, Mellor D, Brands R, Fischer R, Gruber F, Gstraunthaler G, Hellebrekers L, Hyllner J, Jonker FH, Prieto P, Thalen M, Baumans V (2004) The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicol In Vitro 18:1–12

van der Valk J, Brunner D, De Smet K, Fex Svenningsen Å, Honegger P, Knudsen LE, Lindl T, Noraberg J, Price A, Scarino ML, Gstraunthaler G (2010) Optimization of chemically defined cell culture media—replacing fetal bovine serum in mammalian in vitro methods. Toxicol In Vitro 24:1053–1063

Wessmann SJ, Levings RL (1999) Benefits and risks due to animal serum used in cell culture production. Dev Biol Stand 99:3–8